Cabozantinib as a novel therapy for renal cell carcinoma

Current Oncology Reports

Volumn 15, Issue 2, 2013, Pages 76-82

  Vaishampayan, Ulka ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Bone metastases; C Met; Cabozantinib; Renal cancer; VEGF; XL 184

Indexed keywords

AXITINIB; BETA CATENIN; CABOZANTINIB; CYTOKINE RECEPTOR ANTAGONIST; ERLOTINIB; ERYTHROPOIETIN; EVEROLIMUS; FORETINIB; GEMCITABINE; NIVOLUMAB; PLACEBO; PLATELET DERIVED GROWTH FACTOR; ROSIGLITAZONE; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SGX 523; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; TEMSIROLIMUS; TIVANTINIB; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VON HIPPEL LINDAU PROTEIN;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; BREAST CANCER; CASTRATION RESISTANT PROSTATE CANCER; CONCENTRATION LOSS; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG COMPETITION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GENE DUPLICATION; GENE MUTATION; GLIOBLASTOMA; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; IC 50; KIDNEY CANCER; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG CANCER; LUNG CARCINOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; PANCREAS ADENOCARCINOMA; PATHOPHYSIOLOGY; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEINURIA; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMACH CANCER; THYROID MEDULLARY CARCINOMA; TUMOR SUPPRESSOR GENE; VOMITING;

ANILIDES; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; KIDNEY NEOPLASMS; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84879601057     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-012-0289-x     Document Type: Article

References (36)

1. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-34.
2. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-24.
3. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol;28:1061-1068.
4. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet. 2007;370:2103-11.
5. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial. Lancet. 2011;378:1931-9.
6. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271-81.
7. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449-56.
8. Saylor PJ, Escudier B, Michaelson MD. Importance of fibroblast growth factor receptor in neovascularization and tumor escape from antiangiogenic therapy. Clin Genitourin Cancer. 2012;10:77-83.
9. Fernando NT, Koch M, Rothrock C, et al. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors. Clin Cancer Res. 2008;14:1529-39.
10. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res. 2009;15:2207-14.
11. Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10:2298-308.
12. Jiang WG, Martin TA, Parr C, et al. Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit Rev Oncol Hematol. 2005;53:35-69.
13. •• Pàez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009;15:220-31. An experiment depicting the principle that antiangiogenic therapy can eventually promote instead of inhibiting tumor progression.
14. Sattler M, Ma PC, Salgia R. Therapeutic targeting of the receptor tyrosine kinase Met. Cancer Treat Res. 2004;119:121-38.
15. Vankayala H, Lorusso P, Vaishampayan UN. In: Figlin RA, Rathmell WK, Rini BI, editors. C-MET as a novel target for the treatment of renal cell carcinoma. In Renal Cell Carcinoma. New York: Springer; 2012. p. 213-38.
16. Shapiro GI, McCallum S, Adams LM, et al. A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors. Invest New Drugs. 2012 Oct 6. [Epub ahead of print]
17. Wagner AJ, Goldberg JM, Dubois SG, et al. Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: Results of a multicenter phase 2 trial. Cancer. 2012;118:5894-902.
18. •• Choueiri TK, Vaishampayan U, Rosenberg JE, et al. A phase II and biomarker study (MET111644) of the dual Met/VEGFR-2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol. 2012;43:3383-89. First clinical trial of a MET inhibitor in metastatic papillary kidney cancer.
19. Lubensky IA, Schmidt L, Zhuang Z, et al. Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol. 1999;155:517-26.
20. Linehan WM, Pinto PA, Srinivasan R, et al. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Cancer Res. 2007;13:671-9.
21. Pennacchietti S, Michieli P, Galluzzo M, et al. Hypoxia promotes invasive growth by transcriptional activation of the Met protooncogene. Cancer Cell. 2003;3:347-61.
22. Aftab DT, McDonald DM. MET and VEGF: Synergistic targets in castration-resistant prostate cancer. Clin Transl Oncol. 2011;13:703-9.
23. M. S. Gordon, N. J. Vogelzang, P. Schoffski, et al. Activity of cabozantinib (XL184) in soft tissue and bone: Results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors.J Clin Oncol 2011; 29:(suppl; abstr 3010)
24. Knudsen BS, Gmyrek GA, Inra J, et al. High expression of the Met receptor in prostate cancer metastasis to bone. Urology. 2002;60:1113-7.
25. Street J, Lenehan B. Vascular endothelial growth factor regulates osteoblast survival: Evidence for an autocrine feedback mechanism. J Orthop Surg Res. 2009;4:19-23.
26. Grano M, Galimi F, Zambonin G, et al. Hepatocyte growth factor is a coupling factor for osteoclasts and osteoblasts in vitro. Proc Natl Acad Sci USA. 1996;93:7644-8.
27. Ono K, Kamiya S, Akatsu T, et al. Involvement of hepatocyte growth factor in the development of bone metastasis of a mouse mammary cancer cell line. BALB/c-MC Bone. 2006;39:27-34.
28. •• Schimmoller F, Zayzafoon M, Chung LWK, et al. Cabozantinib (XL184), a dual MET-VEGFR2 inhibitor, blocks osteoblastic and osteolytic progression of human prostate cancer xenografts in mouse bone. Mol Cancer Ther. 2011;10:233. Preclinical study depicing the effects of cabozantinib in bone metastases.
29. •• Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial. J Clin Oncol. 2012 Nov 19. [Epub ahead of print] Report of a clinical trial showing the nature of cabozantinib efficacy in bone metastases from prostate cancer.
30. Schoffski P, Elisei R, Müller S, et al. An international, double-blind, randomized, placebo-controlled phase III trial (EXAM) of cabozantinib (XL184) in medullary thyroid carcinoma (MTC) patients (pts) with documented RECIST progression at baseline. J Clin Oncol 2012;30 (suppl; abstr 5508).
31. •• Choueiri TK, Pal SK, McDermott DF, et al. Efficacy of cabozantinib in patients with metastatic refractory renal carinoma (RCC). J Clin Oncol 2012; 30 (abstr 4504): Phase II trial describing the efficacy of cabzantinib in pretreated kidney cancer patients.
32. • Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27:5794-49. A retrospective trial exploring prognostic factors in a large multicenter database of kidney cancer patients treated with VEGF targeted agents.
33. Lee RJ, Michaelson DM, Saylor PJ, et al. Investigator-sponsored trial of efficacy and tolerability of cabozantinib (cabo) at lower dose: A dose-finding study in men with castration-resistant prostate cancer (CRPC) and bone metastases. J Clin Oncol 2012; 30 (suppl; abstr 4566).
34. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-54.
35. Zhang YW, Staal B, Essenburg C, et al. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res. 2010;70:6880-90.
36. ESMO 2012 Press release: Phase III data in treatment of renal cell carcinoma reported. http://www.esmo.org/no-cache/view-news.html